Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Publisher： Karger

E-ISSN： 1423-0232|83|4|177-182

ISSN： 0030-2414

Source： Oncology, Vol.83, Iss.4, 2012-08, pp. : 177-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 135-140

Karger

Access to resources Recommend Favorite

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 3, 2009-01 ,pp. : 151-156

Karger

Access to resources Recommend Favorite

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E1-E11

John Wiley & Sons Inc

Access to resources Recommend Favorite

Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 2-19

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 2-6

Karger

Access to resources Recommend Favorite